Odonate Therapeutics (ODT) Stock Price, News & Analysis

Company Overview

Odonate Therapeutics is a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer. Our initial focus is on the development of tesetaxel, a novel chemotherapy agent that belongs to a class of drugs known as taxanes, which are widely used in the treatment of cancer. Tesetaxel has several potential therapeutic advantages over currently available taxanes, including: oral administration with a low pill burden and a patient-friendly dosing regimen; a formulation that does not contain solubilizing agents that are known to cause hypersensitivity (allergic) reactions; and improved activity against chemotherapy-resistant tumors. Tesetaxel has been generally well tolerated in clinical studies and has demonstrated robust single-agent antitumor activity in two Phase 2 studies in patients with locally advanced or metastatic breast cancer (''MBC'').

Key Stats

• Today's Range: N/A
• 50-Day Range: $1.03 to $1.55
• 52-Week Range: N/A
• Volume: 87,682 shs
• Average Volume: N/A
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

ODT Stock Analysis - Frequently Asked Questions

How were Odonate Therapeutics' earnings last quarter?

Odonate Therapeutics, Inc. (NASDAQ:ODT) released its earnings results on Wednesday, November, 10th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.04) by $0.33.

When did Odonate Therapeutics IPO?

Odonate Therapeutics (ODT) raised $150 million in an IPO on Thursday, December 7th 2017. The company issued 5,900,000 shares at a price of $24.00-$27.00 per share. Goldman Sachs and Jefferies served as the underwriters for the IPO and Cowen was co-manager.

What other stocks do shareholders of Odonate Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Odonate Therapeutics investors own include Intel (INTC), Sorrento Therapeutics (SRNE), AbbVie (ABBV), Energy Transfer (ET), Pfizer (PFE), Exxon Mobil (XOM) and Advanced Micro Devices (AMD).

Company Calendar

• Last Earnings: 11/10/2021
• Today: 5/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:ODT
• CIK: 1717452
• Web: www.odonate.com
• Phone: (858) 731-8180
• Fax: N/A
• Employees: 145
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 28,530,000
• Free Float: 14,578,000
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A